UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 479

Sortiert nach

Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment

Clinical microbiology and infection, 2005-06, Vol.11 (6), p.472-479

2005

Volltextzugriff (PDF)

Volatile fatty acid platform – a cornerstone for the circular bioeconomy

FEMS microbiology letters, 2021-05, Vol.368 (9), p.1

2021

Volltextzugriff (PDF)

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain

Clinical rheumatology, 2020-10, Vol.39 (10), p.2919-2930

2020

Volltextzugriff (PDF)

High resolution climate change projections for the Pyrenees region

Advances in science and research, 2020-09, Vol.17, p.191-208

2020

Volltextzugriff (PDF)

Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency

Expert review of pharmacoeconomics & outcomes research, 2023-11, Vol.23 (10), p.1139-1146

2023

Volltextzugriff (PDF)

Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study

International journal of clinical practice (Esher), 2014-08, Vol.68 (8), p.1001-1009

2014

Volltextzugriff (PDF)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

ClinicoEconomics and outcomes research, 2015-01, Vol.7 (default), p.527-535

2015

Volltextzugriff (PDF)

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

ClinicoEconomics and outcomes research, 2019-07, Vol.11, p.465-475

2019

Volltextzugriff (PDF)

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

Actas urologicas españolas, 2016-10, Vol.40 (8), p.513-522

2016

Volltextzugriff (PDF)

Análisis de coste efectividad de fesoterodina comparado con mirabegron en el marco de tratamiento de primera línea para vejiga hiperactiva con incontinencia urinaria de urgencia, desde la perspectiva del Sistema Nacional de Salud español

Actas urologicas españolas, 2016-10, Vol.40 (8), p.513-522

2016

Volltextzugriff (PDF)

Interleukin-8 production by polymorphonuclear leukocytes from patients with chronic infected leg ulcers treated with Lactobacillus plantarum

Clinical microbiology and infection, 2010-03, Vol.16 (3), p.281-286

2010

Volltextzugriff (PDF)

Bacteriotherapy with Lactobacillus plantarum in burns

International wound journal, 2009-02, Vol.6 (1), p.73-81

2009

Volltextzugriff (PDF)

RWD59 Economic and Healthcare Resource Utilization by Transthyretin Amyloid Cardiomyopathy Patients in Spain: Observations From the PRACTICA Study

Value in health, 2023-12, Vol.26 (12), p.S515

2023

Volltextzugriff (PDF)

Lengua, espacio y sociedad: Investigaciones sobre normalización toponímica en España

Gordón Peral, María Dolores

1, 2013

Volltextzugriff (PDF)

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

Actas urológicas españolas (English ed.), 2016-10, Vol.40 (8), p.513-522

2016

Volltextzugriff (PDF)

EE637 Economic Impact of Managing Invasive Mold Disease With Isavuconazole Compared With Liposomal Amphotericin B in Spain

Value in health, 2023-12, Vol.26 (12), p.S175-S176

2023

Volltextzugriff (PDF)

PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL

Value in health, 2019-11, Vol.22, p.S421-S422

2019

Volltextzugriff (PDF)

POSC38 Study on the Management of Carriers in Hereditary Transthyretin Amyloidosis (EMPATIA): Economic and Healthcare Resource Utilization in Spain

Value in health, 2022-01, Vol.25 (1), p.S93-S94

2022

Volltextzugriff (PDF)

EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

Value in health, 2022-12, Vol.25 (12), p.S58-S58

2022

Volltextzugriff (PDF)

RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

Value in health, 2023-12, Vol.26 (12), p.S508

2023

Volltextzugriff (PDF)

PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

Value in health, 2018-10, Vol.21, p.S362-S362

2018

Volltextzugriff (PDF)

PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

Value in health, 2019-11, Vol.22, p.S904-S904

2019

Volltextzugriff (PDF)

EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain

Value in health, 2023-12, Vol.26 (12), p.S129

2023

Volltextzugriff (PDF)

PMS24 - Economic Evaluations of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review

Value in health, 2017-10, Vol.20 (9), p.A530-A530

2017

Volltextzugriff (PDF)

Economic Evaluations of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review

Value in health, 2017-10, Vol.20 (9), p.A530

2017

Volltextzugriff (PDF)

1 – 25 von 479

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(385)
Mit Volltextzugriff
(400)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment

Volatile fatty acid platform – a cornerstone for the circular bioeconomy

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain

High resolution climate change projections for the Pyrenees region

Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency

Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

Análisis de coste efectividad de fesoterodina comparado con mirabegron en el marco de tratamiento de primera línea para vejiga hiperactiva con incontinencia urinaria de urgencia, desde la perspectiva del Sistema Nacional de Salud español

Interleukin-8 production by polymorphonuclear leukocytes from patients with chronic infected leg ulcers treated with Lactobacillus plantarum

Bacteriotherapy with Lactobacillus plantarum in burns

RWD59 Economic and Healthcare Resource Utilization by Transthyretin Amyloid Cardiomyopathy Patients in Spain: Observations From the PRACTICA Study

Lengua, espacio y sociedad: Investigaciones sobre normalización toponímica en España

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

EE637 Economic Impact of Managing Invasive Mold Disease With Isavuconazole Compared With Liposomal Amphotericin B in Spain

PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL

POSC38 Study on the Management of Carriers in Hereditary Transthyretin Amyloidosis (EMPATIA): Economic and Healthcare Resource Utilization in Spain

EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain

PMS24 - Economic Evaluations of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review

Economic Evaluations of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review

Suchergebnisse filtern